Browse studies
Find your next paid study
4 recruiting studies matching your filters
Lymphoid Malignancies and Precursors: Tissue Acquisition Protocol
Background: \- Lab studies help researchers better understand cancer biology. This information may lead to new methods for diagnosing or treating cancer. To d…
Hodgkin DiseaseLymphoma, Non-HodgkinMultiple Myeloma+2 more
Estimated
~$10 – $675
National Cancer Institute (NCI)NCT01676805
Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
Background: Cancer has a major impact in the United States and across the world. In 2015, over 1.5 million new cases of cancer were diagnosed in the U.S. Rese…
Multiple MyelomaLymphoma, Non-HodgkinLeukemia-Lymphoma, Adult T-Cell+2 more
Estimated
~$10 – $675
National Cancer Institute (NCI)NCT02682667
Phase 1
A Phase I Study to Investigate the Safety, Tolerability, and Preliminary Efficacy of Anti-CD30 Bispecific Antibody-Armed Anti-CD3-Activated Autologous T-Cells (CD30 biAb-AATC) in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies
This first-in-human trial will assess the safety, feasibility, and efficacy of an immunotherapy with a novel CD30 antibody conjugated to a CD3 antibody that is…
Hodgkin DiseaseCD30-Positive Diffuse Large B-Cell LymphomaCD30+ Anaplastic Large Cell Lymphoma+4 more
Estimated
~$10 – $6,250
Medical College of WisconsinNCT05544968
Phase 2
A Phase II Trial of JAK Inhibitor Added to Immunotherapy for Treatment of Relapsed/Refractory T-cell Lymphoma and 9p Amplified Lymphomas
The purpose of this study is to understand and determine if ruxolitinib added to pembrolizumab is safe and effective for the treatment of relapsed or refractor…
Non-Hodgkin LymphomaHodgkin Disease LymphomaNon-Hodgkin Lymphoma Refractory/ Relapsed+5 more
Estimated
~$10 – $7,500
Seda S. ToluNCT07283822